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Letter to the Editor
A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease
To the Editor
Combined immunodeficiencies (CID) include combined defects of
lymphoid cell development and function. We identified a previously
reported heterozygous c.184G>A (pE62K) variant in the RAC2 gene,
in a family with three CID affected members [1].
RAC2 is part of the small Rho GTPase superfamily and is specifically
expressed in hematopoietic cells. RAC2 is involved in ROS production
through NADPH activation and f-actin remodeling, and is activated
upon GTP binding [2]. The GTP/GDP exchange is catalyzed respec-
tively by guanine exchange factors (GEFs) for GTP binding and GTPase
activating proteins (GAPs) for GTP hydrolysis [2]. Normal activity of
RAC2 and other small Rho GTPases were shown to be crucial for neu-
trophil and macrophage motility in larval zebrafish and for normal
lymphocyte development in mice [3,4]. In humans, earlier loss of
function mutations have been described (c.169G>A (p.D57N),
c.167G>A (p.W56X) that cause reduced chemotaxis and ROS pro-
duction in neutrophils and sometimes abnormal lymphocyte numbers
[5,6].
Recently, activating RAC2 variants were described such as the
c.184G>A (pE62K) variant, previously reported by Hsu et al. in three
unrelated CID patients. Here, decreased GTP hydrolysis relayed an in-
crease in active RAC2 leading to severe lymphopenia and neutrophil
dysfunction [1]. They replicated these findings in cell culture-based
experiments and mouse models and showed upregulated signaling that
resulted in increased ROS production and polymerized actin [1]. We
report on three related patients with a similar phenotype that carry this
RAC2-E62K variant, and elaborate on the molecular changes.
The affected members were a 1-year old (P1), his father (P2) and
grandfather (P3). P1 had suffered from respiratory tract infections
(RTIs) requiring treatment with oral antibiotics. P2 and P3 had suffered
from similar recurrent RTIs causing pulmonary damage leading to end-
stage pulmonary failure for which they both required lung transplan-
tation; P3 passed away during this procedure. Lymphocyte phenotyping
of P1 and P2 showed T-cell and B-cell lymphopenia with high relative
percentages of effector/memory T-cells (Supplementary Table S1),
without bone marrow abnormalities. This differed from previously
encountered RAC2 mutations, which did not present with an absolute
CID nor with end-stage pulmonary failure [5,6].
NGS-based immunodeficiency panel analysis showed a hetero-
zygous variant c. 184G>A in RAC2 causing a glutamic acid to lysine
substitution at position 62 (p.E62K). Given the progressive disease
course of P2 and P3, we performed hematopoietic cell transplantation
(HCT) with unrelated cord blood after myelo-ablative conditioning in
P1. Neutrophils reconstituted> 1,8 ∗ 109/mL after 23 days and CD4 T-
cells reconstituted>100 ∗ 106/mL after six months. Absolute CD4,
CD8 and B-cell numbers normalized one year after transplant, during
which P1 suffered from CMV and HHV6 reactivation and acute graft
versus host (GvHD) of the gut and acute chronic GvHD of the skin
which was accompanied by increased numbers of CD4 and CD8 ef-
fector/memory cells. He is being treated with prednisone, tacrolimus
and mycophenolate which sufficiently suppresses his skin GvHD and his
T-cell subsets are normalizing. He currently suffers from frequent in-
fections and his pulmonary function test results are suboptimal. P2 is
clinically well after pulmonary transplantation with normalization of
his pulmonary function test and a reduction of his RTIs. He is still se-
verely immunocompromised with CD4 counts< 100 ∗ 106/mL and
lymphocyte counts< 0.5 ∗ 109/mL.
We used RAC2 crystal structures (PDB IDs 2W2V, 2W2T) and
HADDOCK to structurally investigate variant E62K. We found no direct
effect on GTP binding with minimal atom-atom distances> 1 nm and
hence analyzed Rac2/RacGAP1 interaction [7]. We observed two salt-
bridges in the highest-ranked docked RAC2-RacGAP1 structure that
disappear upon introduction of the mutation (Fig. 1A). This could
hamper GAP binding to RAC2, which would reduce GTP hydrolysis.
To confirm this, we measured relative GTP-bound RAC2 levels in
patient neutrophils [5]. We immunoprecipitated GTP-bound RAC2 with
PAK-loaded beads and found that only after fMLF stimulation there was
a 2-fold increase of GTP-bound RAC2 in patient neutrophils (Fig. 1B).
Data shown is from normalized data, obtained after merging three
controlled experiments that each included healthy donor and patient
data; examples of individual blots are shown.
To assess neutrophil function, we cultured neutrophils in 3D fibrin
matrices [8]. Migratory speed was reduced by 50% (Fig. 1C) and when
cultured with GFP-expressing S. aureus we found reduced bacterial
killing, triggering outgrowth of S. aureus at a concentration of 5× 106/
mL and a multiplicity of infection of one (Fig. 1D).
Finally, we investigated the suppressed T-cell numbers in RAC2-
E62K patients, which could be caused by decreased thymic emigration,
because the patients expressed no bone marrow abnormalities, and
normal thymic populations and outgrowth in RAC2-E62K mice were
found [1]. The number of CD4 T-cells expressing recent thymic emi-
grant (RTE) markers were severely reduced in both patients, but par-
tially restored in P1 after HCT (Fig. 1E). These results could be biased
by relative abundance of effector memory T-cells that were previously
shown in RAC2 patients and in P2, however, P1 had relatively normal
naive and effector/memory numbers before transplantation and only
showed an expansion of memory T-cells after transplant. Thus, the
lymphopenia in RAC2-E62K patients could involve disturbances in
RAC2 signaling-mediated chemotactic function of (precursor) T-cells.
This additional data supports that deficient GAP binding is the un-
derlying cause for the clinical phenotype of the recently reported RAC2-
E62K variant [1]. It corroborates that internal non-catalyzed GTP hy-
drolysis is sufficient to regulate RAC2 activation under unstimulated
conditions. When patient neutrophils become activated, however, GAPs
cannot bind efficiently and consequently GTP-bound RAC2 increases.
The same mechanism might be relevant for other RAC2 variants at the
interface with GAP binding, supported by the fact that patients with a
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Fig. 1. A. Docked model of the RAC2-RacGAP1 complex; the right panel zooms in on the interface region that includes residue E62 of RAC2 (highlighted in ball-and-
stick representation, carbon atoms in green). Within the complex, RAC2 is the protein on the right-hand side, RacGAP1 is given in pink. Two candidates for salt-
bridge formation with E62 (K423 and R427 of RacGAP1) are shown in ball-and-stick representation with carbons in magenta; atomic distances are indicated in Å.
Other key residues for RacGAP1 binding (N495, black; G388, grey) are also highlighted.
B. GTP-bound RAC2 ratio, normalized for GTP-bound RAC2 at t=0, both father and son have significantly more GTP-bound RAC2 after 15 seconds of stimulation
with fMLF (1μM, one-way ANOVA, p<0,05) when compared to neutrophils of one healthy donor. This effect was replicated twice after which the average GTP-
bound ratios were compared.
C. Chemotaxis of affected neutrophils compared to a healthy control. Both the track speed (left) and distance (right) of patient neutrophils is diminished when
compared to healthy controls when stimulated with fMLF in varying concentrations of fibrin gel (concentration under y axis).
D. Fluorescence after incubation of GFP-expressing S. aureus with healthy and patient neutrophils. Patient neutrophils are incapable of killing S. aureus resulting in
immediate colonization at an S. aureus concentration of 5 x 106 (S4A), at a concentration of 10 x 106 the healthy neutrophils can also not prevent S. aureus from
growing.
E. Number of recent thymic emigrants in father (P2) and son (P1) compared to adult healthy controls (HC) and cord blood of two new-borns (CB) in the CD4 T-cell
population gated as CD3+, CD4+, CD8-, CD45RA+, CD27+, CD25+, CD62L-, CD31-, and CD21+.
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P34H mutation show a similar phenotype [7,9].
The increase in GTP-bound RAC2 might impede physiological f-
actin polymerization, which could cause neutrophilic dysfunction, and
possibly, the underlying lymphopenia by hampering thymic emigra-
tion. This is reminiscent of phenotypes of WASp and DOCK8 variant
cells, which are both effectors of the small GTPase Cdc42 [10].
In conclusion, we report additional clinical and molecular findings
on the recently discovered dominant activating RAC2-E62K variant,
which we found in three related patients. Our data support that the
RAC2-E62K variant leads to more GTP-bound, active RAC2 by ham-
pered GAP binding.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.clim.2019.108248.
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